Last reviewed · How we verify

NCT03459976: HE4

HE4 is a Beneficial Biomarker in Endometrial Cancer

Status unknown Last updated 25 January 2019
What this trial tests

trial testing evaluate serum level HE4 in endometrial cancer in Endometrial Cancer in 87 participants. Status unknown.

Timeline
1 December 2017
Primary endpoint
1 April 2019
1 April 2019

Quick facts

Lead sponsorAin Shams University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment87
Start date1 December 2017
Primary completion1 April 2019
Estimated completion1 April 2019
Sites3 locations across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Ain Shams University

Who can join

Adults 40 to 70, female only, with Endometrial Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluation of Serum level of Human Epididymis Secretory Protein 4 (HE4) in Endometrial Cancer and clinical significant it

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Endometrial Cancer

Currently open trials in the same condition.

Other Ain Shams University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03459976.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing